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cGVHD. 12 pts have relapsed at a median of 128 days (range
76-512) post transplant with a one year actuarial OS of 65%.
Conclusion: This approach permits accurate delivery of a targeted
systemic exposure to IV busulfan, is well-tolerated, and will allow
additional dose escalation. Relapse, as opposed to toxicity, remains
the major challenge.
274
TREOSULFAN: AN ATTRACTIVE ALTERNATIVE IN THE CONDITIONING
IN BONE MARROW TRANSPLANT FOR THALASSEMIA
Smiers, F.J.1, Bredius, R.1, Ball, L.1, Lankester, A.1, Bakker, H.2,
Egeler, R.M.1 1Dept Pediatric Hemato Oncology and Bone Marrow
Transplantation, Leiden University Hospital, Leiden, Netherlands;
2Data Management Dept Pediatric Hemato Oncology and Bone Marrow
Transplantation, Leiden University Hospital, Leiden, Netherlands.
Traditionally Busulfan and Cyclofosfamide are used with or
without serotherapy in the conditioning for beta thalassemia. Due
to a high rejection rate in our institution, Melfalan has been added
resulting in a marked reduction of rejection. Toxicity of this reg-
imen is tolerable and consists mainly of mucositis and occasionally
of VOD.
Treosulfan is an alkylating agent with a supposedly lower toxicity
proﬁle than other alkylating agents.
In 12 previously treated thalassemia patients (class 2-3) condi-
tioned with Busulfan, Melfalan, Cyclofosfamide and serotherapy,
mucositis WHO grade 1-2 was seen in 2 patients and grade 3– 4 in
9 patients. VOD was seen in 4 patients and 2 patients had mild
VOD. One patient died due to MOF. Acute GVHD was seen in 6
patients. Chronic GVHD (mild) in 2 patients. Two patients re-
jected but were successfully retransplanted. Ten patients had full
donor chimerism, two patients showed stable mixed chimerism.
In comparison the results in 5 beta thalassemia patients (class 2-3)
conditioned with Treosulfan 10 -14 mg/m2, Cyclofosfamide 120
mg/kg, Melfalan 140 mg/m2 with additional serotherapy (either
ATG or Campath). Two patients had a matched unrelated donor,
3 patients had identical related donors. Three patients received
Treosulfan 10 mg/m2. One patient rejected early and was success-
fully retransplanted with Treosulfan 14 mg/m2. The remaining
two patients received Treosulfan 14 mg/m2. Engraftment was in
normal range. No acute or chronic GVHD was seen. Mucositis
was limited in 3 (WHO grade 2) and moderate to severe (WHO
grade 3-4) in 2 patients. No VOD was seen. Chimerism was stable
mixed in 2 and full donor in three.Conclusion: Treosulfan 14
mg/m2 is well tolerated in thalassemia bone marrow transplant
patients and shows a lower toxicity proﬁle than busulfan.
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IMPACTS OF COMORBIDITIES ON OUTCOMES OF PATIENTS (PTS)
YOUNGER THAN 60 YEARS OLD, DIAGNOSED WITH INDOLENT MALIG-
NANCIES AND TREATED WITH ALLOGENEIC HEMATOPOIETIC CELL
TRANSPLANTATION (HCT): A MODEL FOR PTS WITH AUTOIMMUNE
DISEASES
Sorror, M.L.1, Storb, R.1,2, Storer, B.1,2, Maloney, D.G.1,2,
Sandmaier, B.M.1,2 1Fred Hutchinson Cancer Research Center; 2Uni-
versity of Washington, Seattle, WA.
The NIH has stated the growing need to explore the therapeutic
and curative potential of allogeneic HCT for autoimmune diseases
(BBMT 2005, 11:862). The safety of HCT in pts with signiﬁcant
comorbidities is of a concern. Here, we analyzed whether the
HCT-CI, a sensitive tool to capture comorbidities (Blood 2005,
106:2912), could assess how young (60 year old) pts with indolent
malignancies tolerated allogeneic HCT strategies as a hypothetical
model for pts with autoimmune diseases. A majority of pts received
myeloablative (MA) conditioning (n364) with cyclophosphamide
plus busulfan (79%) or 12 Gy TBI (21%), while a small group of
pts (n79) received nonmyeloablative (NMA)-conditioning with 2
Gy total body irradiation (18%) 90 mg/m2 of ﬂudarabine (82%).
Diagnoses were acute myeloid leukemia in 1st remission (27%),
chronic myeloid leukemia-chronic phase (40%), myelodysplasia-
refractory anemia (16%), chronic lymphocytic leukemia (8%), low
grade non-Hodgkin lymphoma (4%), and others (5%). At HCT,
NMA-pts differed from MA-pts with respect to age (median 52 vs
41 years,), prior high-dose HCT (9% vs 1%), unrelated grafts
(42% vs 31%), and G-PBMC as stem cell source (87% vs 49%).
HCT-CI scores of 1-2 and 3 were found among 33% and 35%
of NMA vs 35% and 17% of MA-pts, respectively. The most
frequent comorbidities were pulmonary (24%) and hepatic (16%).
After HCT, 4-year cumulative incidences of non-relapse mortality
(NRM) were 10%, 17%, and 36% for MA-pts with HCT-CI
scores of 0, 1-2, and 3, respectively. Proportional hazards mod-
els; adjusted for stem cell source, pt age, donor type, and diagnoses,
were used to estimate hazard ratios (HR) for NRM and survival.
MA-pts with HCT-CI scores of 1-2 or 3 had higher adjusted
HRs for NRM (1.85, p0.06 and 4.56, p0.0001) and all-cause
mortality (2.15, p0.003 and 4.59, p0.0001) compared to pts with
HCT-CI scores of 0. There were no statistically signiﬁcant differ-
ences in NRM between NMA and MA-pts with HCT-CI scores of
0, 1-2, or 3 ( p0.7, p0.1, p0.18, respectively); however, the
small numbers of pts receiving NMA conditioning in each stratum
limited the power of these comparisons. We conclude that among
young pts with indolent malignancies, NRM and survival are
strongly associated with comorbidity after MA-HCT. Therefore,
MA-HCT for treatment of autoimmune diseases might be contra-
indicated for pts with HCT-CI scores of 3. Additional data are
needed to clarify the usefulness of NMA-HCT in indolent dis-
eases.
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OUTCOME OF PATIENTS ACCORDING TO ETHNIC GROUPS RECEIVING
ALLOGENEIC STEM CELL TRANSPLANTATION IN MALAYSIA
Tan, S.M.1, Chang, K.M.1, Ong, T.C.2, Salleh, S.1, Sathar, J.1,
Purushothaman, V.1 1Hospital Kuala Lumpur, Kuala Lumpur,
Wilayah Persekutuan, Malaysia; 2Hospital Sultanah Aminah, Johor
Bahru, Johor, Malaysia.
A total of 106 patients received an allogeneic stem cell transplan-
tation at Kuala Lumpur Hospital between 5/1999 and 5/2006.
Majority received G-CSF stimulated bone marrow as stem cell
source while 20% received PBSC. The race distribution were 52%
Malays, 31% Chinese, 9% Indians and 9% other races. The me-
dian time to neutrophil engraftment was 19 days and platelet
engraftment was 18 days. There was no difference in engraftment
days of platelets and neutrophils between G-CSF stimulated mar-
row and PBSC. The overall survival OS was 61%, event-free
survival EFS was 54% and the 100-day transplant mortality rate
TRM was 16%. The cumulative relapse rate was 24% and the
graft-vs-host disease GVHD rate was 32%.
The overall survival rate according to race was 62% in Malays,
68% in Chinese and 50% in Indians. The cause for mortality in the
Malay race was GVHD at 52%, relapse 29% and infection 29%.
Amongst the Chinese, the major cause for mortality was relapse
60%, GVHD 20% and infection 10%. In the other races, the cause
of mortality was relapse in 70% and GVHD in 20%.
The incidence of moderate Grade II and severe Grade III-IV
acute GVHD was 40% and 29% in the Malays, 43% and 10% in
the Chinese and 22% and 22% in the Indians respectively. Simi-
larly the incidence of limited and extensive chronic GVHD was
12% and 34% in the Malays, 21% and 18% in the Chinese and 0%
and 38% in the Indians.
It is evident that the incidence of severe acute GVHD and
extensive chronic GVHD is higher in the Malays than the other
races. Severe GVHD was also the major cause of mortality
amongst the Malays than the other races. However the rate of
relapse was inversely lower in the Malays than in the Chinese and
Indians.
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ALLOGENEIC HEMATOPOIETIC CELL TRANSPLANTATION IN IMATINIB
ERA: A SINGLE CENTER COMPARATIVE ANALYSIS OF IMATINIB RE-
CEIVING PATIENTS TO IMATINIB NAIVE PATIENTS
Ugur Bilgin, A.1, Soydan, E.1, Topcuoglu, P.1, Arslan, O.1, Ozcan, M.1,
Gurman, G.1, Demirer, T.1, Akan, H.1, Beksac, M.1, Konuk, N.1,
Poster Session II100
Uysal, A.1, Ilhan, O.1, Arat, M.1 1Ankara University School of Medi-
cine, Department of Hematology and Stem Cell Transplantation Unit,
Ankara, Turkey.
Imatinib has become the standard primary approach for the
treatment of a newly diagnosed chronic phase myeloid leukemia
(CML) patient, recently. Complete cytogenetic response is
achieved on the majority of patients under treatment, but the
disease remains in molecular level and after discontinuation of the
drug, relapses occur inevitably. In imatinib era centers are referring
only the patients, who has imatinib resistance or patients with high
relapse risk. Secondly, the period from diagnosis to transplantation
is an important nominator. In imatinib era CML patients will ﬁrst
undergo a trial of imatinib and according to the response they will
be referred to the allogeneic transplant program. There is lack of
data about the impact of delayed referral and emerging imatinib
resistance on allogeneic transplant outcome. We have performed a
case-matched control analysis in our CML (n: 173). CML patients
who received imatinib before transplantation (n20), were
matched according EBMT (Gratwohl) score with imatinib naive
ones (n40). The median age at transplant in the imatinib group
was 39 (19-57), gender F/M: 10/10, disease status 1st CP:13, 2nd
CP: 4, AP: 2, BP: 1. The median total imatinib dose that was used
until transplantation was 93gr (33-648), and imatinib therapy was
discontinued at a median of 17, 5 (7-210) days prior to the trans-
plantation. Only one of 20 patients was in molecular remission
before transplantation. according to the EBMT score. The median
age of 40 patients in imatinib naı¨ve group was 34 years (14-53),
gender F/M: 14/26, and disease status 1st CP:32, 2nd CP:2, AP: 3,
BP: 3. The two groups were similar according to their age, sex,
conditioning regimen, stem cell sources and Grathwohl scores.
Engraftment for neutrophil 0,5109/L, and platelet 
20109/L was median 15 (13-20) days and 13 (10-32) days in the
imatinib group while it is 16 (0-28) days and 15 (0-36) days in the
imatinib naive group. The response to transplantation, transplan-
tation related mortality, the incidence of acute and chronic
GVHDH for each group were not signiﬁcantly different. More-
over, no signiﬁcant difference was determined between 2-year’s
disease free survival and overall survival rates (Table). Our single
center analysis is in concordance with several recent reports. In this
study, it is observed that imatinib use prior to AHSCT does not
negatively affect the early transplant related outcome.
STI () n: 20 STI (-) n: 40 p
Median age 39 (18-57) 34 (14-53) 0,160
Grathwohl score
(1,2,3,4) 1/2/7/6/4 1/6/20/10/3 0,545
Time Diagnosis-
Transplant (month) 16,9 (5,4-75,8) 11,6 (4,2-129,3) 0,076
Stem cell source (PB/
BM) 15/5 30/10
Conditioning regimen
(Ablative/RIC) 10/10 28/12 0,161
Sex (Female/Male) 10/10 14/26 0,751
Engraftment 19/20 39/40 0,559
NEU>0.510e9/L 15 (13-20) 16 (0-28) 0,639
Transplantation-
related mortality 3/20 6/40 1
Acute GvHD (II-IV) 3/19 17/40 0,076
Chronic GvHD 8/16 22/34 0,322
Relapse rate 3/20 14/40 0,136
2-year’s disease free
survival % 55,4%13,2 % 46,7%7,9 0,595
2-year’s overall
survival %71,513,4 % 59,4%7,9 0,463
PB: Peripheral blood, BM: Bone morrow, RIC: Reduced intensity
conditioning
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HUMAN HERPESVIRUS-6 ENCEPHALITIS FOLLOWING ALLOGENEIC HE-
MATOPOIETIC STEM CELL TRANSPLANTATION
Vu, T.1,2,3, Kamble, R.1,2,3, Oholendt, M.1,2,3, Scholoff, A.1,2,3,
Obi, G.1,2,3, East, K.1,2,3, Hutton, G.1,2,3, Heslop, H.1,2,3,
Brenner, M.1,2,3, Carrum, G.1,2,3 1Center for Cell and Gene Therapy,
Houston, TX; 2Baylor College of Medicine, Houston, TX; 3The Meth-
odist Hospital, Houston, TX.
Approximately 50% recipients of allo-HSCT develop human
herpes virus-6 (HHV-6) viremia detectable by polymerase chain
reaction ampliﬁcation (HHV-6 PCR), but the clinical signiﬁcance
of this asymptomatic viremia is unclear. Five of 53(9.4%) patients
who received Alemtuzumab (total dose, 40 mg) supported condi-
tioning (CY-TBI 3, BU-TBI1, Flu-Mel1, MUD 3,
MMUD 1, MMRD1) and Tacrolimus as GVHD prophylaxis
subsequently developed HHV-6 encephalitis whilst receiving an-
tiviral prophylaxis (Valciclovir 4 and Valganciclovir 1). Acute
GVHD (grade II 1, grade III2, grade IV2) preceded enceph-
alitis and had necessitated, prednisone 5, Inﬂiximab 1, Alemtu-
zumab 1, and Daclizumab 1. HSV-6 encephalitis became ap-
parrent at 41-103 days (median 60 days) presenting with confusion
(n5), amnesia (n 3) and seizures (n2). MRI revealed non-
speciﬁc white matter changes in 4 and a non enhancing medial
temporal lobe lesion in one of the patients. CSF protein was
elevated in 4 patients (table-1); CSF-pleocytosis was mild with a
median of 3- lymphocytes/hpf. HSV-6 PCR on blood (plasma)
revealed 100-22,500 (median 1200) DNA copies/ml. CSF PCR
was positive in all 5 patients at 600-225,000 (median 4700) copies/
ml). CSF HHV6 was several fold higher than plasma levels (table-
1). EEG was nonspeciﬁc in all 5 patients. Intravenous administra-
tion of foscarnet resulted in neurological improvement at 8-13
(median 11) days and negative plasma PCR at 30-66 (median 50)
days; recovery of short-term memory loss was more prolonged. In
the patient with negative plasma PCR, CSF PCR became negative
on 50th day of therapy. Four patients had complete neurological
recovery; one patient (#2) had transient improvement before suc-
cumbing to multi-organ failure. We conclude that, HSV-6 en-
cephalitis complicates approximately 10% of in vivo T cell depleted
allo-HSCT. Poor yield of routine CSF, MRI and EEG examina-
tion calls for high index of suspicion and CSF examination for
HHV-6 PCR. Prompt antiviral treatment with foscarnet appears
effective.
Table-1: HSV-6 Encephalitis following allo-HSCT
Age/
Sex
Onset/
Day Manifestation
HSV-6
CSF
(copy/ml)
HSV-6
Blood
(copy/ml) Outcome
Other
viral
infections
Follow-up
Months
46F 41 Amnesia,
confusion,
seizure
4700 Negative Complete
resolution
Herpes
zoster
Alive 12
months
66F 103 Confusion,
somnolence,
disorganized
speech
225,000 22,500 Transient
improvement
CMV Died day
147
41M 60 Amnesia,
confusion
Positive* 200 Complete
resolution
None Alive 36
months
39M 35 Amnesia,
confusion,
tremor
4800 100 Complete BK virus
resolution
Alive 6
months
58F 83 Seizure,
confusion
600 2700 Complete
resolution
None Died day
120
Abbreviations: M- male, F- female, allo-HSCT- allogeneic hema-
topoietic stem cell transplant, MRI- Magnetic resonance im-
aging, HHV- Human herpes virus, Prot- Protein, Leu- Leu-
kocytes, CSF- Cerebrospinal ﬂuid, WM- white mater, *
Quantitative PCR not available
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CD154:CD40 CO-STIMULATORY BLOCKADE AT PRIMARY BMT PRO-
MOTES ALLOGENEIC ENGRAFTMENT IN SECONDARY BMT BY BLOCK-
ING SENSITIZATION
Xu, H.1, Huang, Y.1, Hussain, L.-R.1, Yan, J.1, Ildstad, S.T.1 1Institute
for Cellular Therapeutics, University of Louisville, Louisville, KY.
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